In parallel, obesity modifies drug disposition at every pharmacokinetic step, expanding the distribution volume for lipophilic agents such as calcineurin and mTOR inhibitors, altering CYP3A metabolism, and increasing interindividual variability in exposure. The gene discussed is MTOR; the disease is obesity due to melanocortin 4 receptor deficiency.